Aktiv Pharma Group, Inc news
Broomfield, Colorado, 10/3/2022. Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project BioShield Act, Aktiv will supply emergency autoinjectors containing pralidoxime chloride (2-PAM) to the CH
Broomfield Colorado 6/16/2022. Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). The ETP is a collaborative effort which supports the FDA’s mission to facilitate modernization in the pharmaceutical industry and helps pharmaceutical companies redu
Broomfield Colorado 6/25/2022. Aktiv Pharma Group (Aktiv) announced today a grant award from the U.S. Department of Defense (DOD) Defense Health Agency (DHA) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) [1] for the continued development of a tranexamic acid (TXA) autoinjector, targeting proposed indications related to prehospital treatment of severe bleeding.
Many public services, e.g. the public school system, make up resource deficits by soliciting or accepting private charitable donations. This strategy does not work for prescription drug donations as they require a medical order for sale to a private customer; a prospective donor can’t simply walk into Walgreens and buy epinephrine, heparin, insulin, Zofran, Dilaudid or ketamine. Emergency services in the United States are often reliant on traditional retail pharmacies to source medicati
[BROOMFIELD, CO – 31 MARCH 2020] Shortly after receiving a $24.5 million project from the Department of Defense (DOD) to develop a scopolamine auto-injector, Aktiv Pharma Group has been awarded a $16 million contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). Under this contract, Aktiv Pharma Group will advance a pralidoxime chlo